A manufacturing delay is stymying progress of a clutch of Autolus’ CAR-T programs. Autolus revealed the setbacks alongside news that it is dumping the first-generation version of AUTO2 in the face of tough competition in the BCMA space. The manufacturing issue, which is affecting three Autolus’ programs, relates to a five-month delay in the timeline for qualifying the U.K.’s Cell Therapy Catapult. Autolus’ clinical trial manufacturing site at Catapult was licensed in March and has supplied materials to studies since then. But the ramp-up of output has been slowed by delays at the broader Catapult complex. Source: Fierce Biotech 9/8/2019